IAS World AIDS 2022 Conference Update
Catching Up On Advancements & Strategies
IAS World AIDS 2022 Conference Update
MAO LUNCH & LEARN PROGRAM
presented by the Medical Advocacy and Outreach (MAO) Department of Education and Training
IN-PERSON TRAINING/Virtual Participation Possible
with support from
Wednesday, October 12, 2022
12 PM – 1 PM CST
All participants may be required to complete a post-participation evaluation.
ALL registrations MUST be completed by Noon on Friday, October 7th!
Physical Location:
MAO Learning Center
2530 Fisk Road
Montgomery, Alabama 36111
IN-PERSON PARTICIPATION AT THE MAO LEARNING CENTER WILL BE LIMITED TO 30 PARTICIPANTS.
A VIRTUAL Option (without lunch) is available.
PARTICIPATION IS FREE
PRESENTATION OBJECTIVES:
This presentation will:
- To understand the durable power of Biktarvy after a 5 year study, with 0 cases of resistance
- Identifying late presenters or HTE MDR PLWH and the best treatment options available
- To discuss long term injectable risks and benefits
Corinne “Corie” Beniasians, PA-C, MS-PA, MS, is an HIV Treatment Medical Scientist affiliated with Gilead Sciences.
PRESENTATION SYNOPSIS:
The most recent updates in HIV care management, based on data presented at the recent IAS World AIDS 2022 Conference, covering topics of Biktarvy 5 year data, novel capsid inhibitor SQ ARV Lenacapavir, management of HIV/HBV coinfection, pediatric Biktarvy dosing, management of HTE MDR PLWH, weight change with ARV, rapid start, prognosis of late presenters, and much more.
Assistance:
Should you have questions about this training and its content, email [email protected].
Should you experience difficulty with the online registration process email [email protected].
Contact Hours/Credit Statement (s): NO Contact Hours are officially provided for participation in this program.
Conflict of interest: There is no conflict of interest for anyone in a position to control content for this activity.
Joint Providers: This activity is provided independently by MAO.
Please check back soon!
This campaign has ended or is not currently active.
Contact us if you would like more information on how to support!